Limit Fluoroquinolone Use in Light of Risks, FDA Says

The US Food and Drug Administration (FDA) said today that unless they lack other treatment options, patients with uncomplicated infections should not receive fluoroquinolones, given the risk for disabling and potentially permanent adverse events.

Labels for these antibiotics already warn about the risks for tendonitis, tendon rupture, central nervous system effects, peripheral neuropathy, myasthenia gravis exacerbation, QT prolongation and torsades de pointes, phototoxicity, and hypersensitivity. These adverse events can occur together. The FDA will update the labels to state that the serious risks posed by fluoroquinolones generally outweigh their benefits for patients with sinusitis, bronchitis, and uncomplicated urinary tract infections that are treatable by other means.

There are seven FDA-approved fluoroquinolones for systemic use on the market:

  • moxifloxacin (Avelox, Merck),

  • ciprofloxacin (Cipro, Bayer HealthCare),

  • ciprofloxacin extended-release,

  • gemifloxacin (Factive, LG Life Sciences, Inc),

  • levofloxacin (Levaquin, Janssen Pharmaceuticals Inc),

  • moxifloxacin injection, and

  • ofloxacin (available only as a generic).

An FDA advisory panel in November 2015 recommended stronger label warnings for the antibiotics, given widespread reports of adverse events.


Limit Fluoroquinolone Use in Light of Risks, FDA Says. Medscape. May 12, 2016.

Health Solutions From Our Sponsors